Specifically, 12 weeks of treatment with GLP‐1R agonists in T2D patients (data about the sex of participants are not reported) reduced inflammation significantly by reducing the production of ROS, inflammatory mediators like TNF‐α/IL‐1β, and NFκB activation in blood mononuclear cells [176]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.